Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28204538 | 0.93 | TSHR (0.43) | TSHR | |
| Dimethylformamide SCHEMBL23457380 | 0.92 | TSHR (0.47) | TSHR | |
| Dimethylformamide SCHEMBL731136 | 0.88 | — | — | |
| Dimethylformamide SCHEMBL333489 | 0.88 | — | — | |
| Dimethylformamide SCHEMBL11280350 | 0.88 | — | — | |
| Dimethylformamide SCHEMBL288973 | 0.85 | — | — | |
| Dimethylformamide SCHEMBL17748325 | 0.82 | TSHR (0.56) | TSHR | |
| Dimethylformamide SCHEMBL23282482 | 0.81 | TSHR (0.47) | TSHR | |
| Dimethylformamide SCHEMBL10916154 | 0.81 | ALDH1A1 (0.47) | TSHR | |
| Dimethylformamide SCHEMBL1668233 | 0.79 | TSHR (0.60) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808324-A1 | PYRROLE COMPOUND | Kabushiki Kaisha Yakult Honsha (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-20140343017-A1 | PYRROLE COMPOUND | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-11-20 | — | — | US | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343017-A1 | PYRROLE COMPOUND | TUBB3, TUBB1, TUBB | TSHR 1730/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | TSHR 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.